Selective Optimization of Side Activities (SOSA): A Promising way for Drug Discovery

Polypharmacology in Drug Discovery

Volumn , Issue , 2012, Pages 227-243

  Langer, Thierry ^a   Wermuth, Camille Georges ^a  

^a Prestwick Chemical   (France)

Author keywords

Pharmacophore concept, principle of bioisosterism; SOSA, a promising way to drug discovery; SOSA designed drug library, and druglike hits

Indexed keywords

EID: 84886004148     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118098141.ch11     Document Type: Chapter

References (75)

1. Sternbach, L. H. (1979), The benzodiazepine story, J. Med. Chem. 22, 1-7.
2. Raju, T. N. K. (2000), The Nobel chronicles, Lancet 255, 1022-1024.
3. Wermuth, C. G. (1998), Search for new lead compounds: The example of the chemical and pharmacological dissection of aminopyridazines, J. Heterocycl. Chem. 35, 1091-1100.
4. Wermuth, C. G.; Clarence-Smith, K. (2000), "Drug-like" leads: Bigger is not always better, Pharm. News 7, 53-57.
5. Wermuth, C. G. (2001), The "SOSA" approach: An alternative to high-throughput screening, Med. Chem. Res. 10, 431-439.
6. Wermuth, C. G. (2004), Selective optimization of side activities: Another way for drug discovery, J. Med. Chem. 47, 1303-1314.
7. Wermuth, C. G. (2006), Selective optimization of side activities: The SOSA approach, Drug Discov. Today 11, 160-164.
8. Muramatsu, M.; Tamaki-Ohashi, J.; Usuki, C.; Araki, H.; Chaki, S.; Aihara, H. (1988), 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices, Eur. J. Pharmacol. 153, 89-95.
9. Biziere, K.; Worms, P.; Kan, J. P.; Mandel, P.; Garattini, S.; Roncucci, R. (1985), Minaprine, a new drug with antidepressant properties, Drugs Exp. Clin. Res. 11, 831-840.
10. Biziere, K.; Kan, J. P.; Souilhac, J.; Muyard, J. P.; Roncucci, R. (1982), Pharmacological evaluation of minaprine dihydrochloride, a new psychotropic drug, Arzneim.-Forsch. 32, 824-831.
11. Ferretti, P.; Algeri, S.; Benfenati, F.; Cimino, M.; Ferretti, C.; Garattini, S.; Lipartiti, M. (1984), Biochemical effects of minaprine on striatal dopaminergic neurons in rats, J. Pharm. Pharmacol. 36, 48-50.
12. Kan, J. P.; Mouget-Goniot, C.; Worms, P.; Biziere, K. (1986), Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat, Biochem. Pharmacol. 35, 973-978.
13. Garattini, S.; Forloni, G. L.; Tirelli, S.; Ladinsky, H.; Consolo, S. (1984), Neurochemical effects of minaprine, a novel psychotropic drug, on the central cholinergic system of the rat, Psychopharmacology (Berlin) 82, 210-214.
14. Worms, P.; Kan, J. P.; Wermuth, C. G.; Roncucci, R.; Biziere, K. (1987), SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents, J. Pharmacol. Exp. Ther. 240, 241-250.
15. Worms, P.; Kan, J. P.; Steinberg, R.; Terranova, J. P.; Perio, A.; Biziere, K. (1989), Cholinomimetic activities of minaprine, Naunyn-Schmiedeberg's Arch. Pharm. 340, 411-418.
16. Passeri, M.; Cucinotta, D.; de Mello, M.; Bizi[1]ere K. (1987), Int. J. Geriatr. Psychiatry 2, 97-103.
17. Donnelly, R.; Elliott, H. L.; Meredith, P. A.; Reid, J. L. (1990), Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects, J. Cardiovasc. Pharmacol. 16, 790-795.
18. Chopra, L. C.; Twort, C. H. C.; Ward, J. P. T. (1992), Direct action of BRL 38227 and glibenclamide on intracellular calcium stores in cultured airway smooth muscle of rabbit, Br. J. Pharmacol. 105, 259-260.
19. Challiss, R. A. J.; Patel, N.; Arch, J. R. S. (1992), Comparative effects of BRL 38227, nitrendipine and isoprenaline on carbachol-and histamine-stimulated phosphoinositide metabolism in airway smooth muscle, Br. J. Pharmacol. 105, 997-1003.
20. Okada, Y.; Yanagisawa, T.; Taira, N. (1993), BRL 38227 (levcromakalim)-induced hyperpolarization reduces the sensitivity to calcium of contractile elements in canine coronary artery, Naunyn-Schmiedeberg's Arch. Pharm. 347, 438-444.
21. Lee, Y. S.; Sayeed, M. M.;Wurster, R. D. (1994), In vitro antitumor activity of cromakalim in human brain tumor cells, Intnatl. J. Exp. Clin. Pharmacol. 49, 69-74.
22. Silvestri, R.; Artico, M.; La Regina, G.; Di Pasquali, A.; De Martino, G.; D'Auria, F.D.; Nencioni, L.; Palamara, A. T. (2004), Imidazole analogues of fluoxetine, a novel class of anti-Candida agents, J. Med. Chem. 47, 3924-3926.
23. Chong, C. R.; Qian, D. Z.; Pan, F.; Wei, Y.; Pili, R.; Sullivan, D. J. Jr., ; Liu, J. O. (2006), Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target, J. Med. Chem. 49, 2677-2680.
24. Chong, C. R.; Chen, X.; Shi, L.; Liu, J. O.; Sullivan, D. J., Jr., (2006), Aclinical drug library screen identifies astemizole as an antimalarial agent, Nature Chem. Biol. 2, 415-416.
25. Zhou, Z.; Vorperian, V. R.; Gong, Q.; Zhang, S.; January, C. T. (2007), Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole, J. Cardiovasc. Electrophys. 10, 836-843.
26. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. (2001), Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 46, 3-26.
27. Veber,D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.;Ward, K.W.;Kopple, K. D. (2002), Molecular properties that influence the oral bioavailability of drug candidates, J. Med. Chem. 45, 2615-2623.
28. Bergström C. A. S.; Strafford M.; Lazorova L.; Avdeef A.; Luthman K.; Artursson P. (2003), Absorption classification of oral drugs based on molecular surface properties, J. Med. Chem. 46, 558-570.
29. Wenlock M. C.; Austin R. P.; Barton P.; Davis A. M.; Leeson P. D. (2003), A comparison of physiochemical property profiles of development and marketed oral drugs, J. Med. Chem. 46, 1250-1256.
30. Huang, Z.; Ducharme, Y.; MacDonald, D.; Robichaud, A. (2001), The next generation of PDE4 inhibitors, Curr. Opin. Chem. Biol. 5, 432-438.
31. Randolph, J. T.; Sauer, D. R.; Haviv, F.; Nilius, A. M.; Greer, J. (2004), Elimination of antibacterial activities of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A, Bioorg. Med. Chem. Lett. 14, 1599-1602.
32. Kodukula, K.; Arcuri, M.; Cutrone, J. Q.; Hugill, R. M.; Lowe, S. E.; Pirnik, D. M.; Shu, Y.-Z. (1995), BMS-192548, a tetracyclic binding inhibitor of neuropeptide Y receptors, from Aspergillus niger WB2346, J. Antibiot. (Tokyo) 48, 1055-1059.
33. Gaud, A.; Simon, J.-M.;Witzel, T.; Carre-Pierrat, M.;Wermuth, C. G.; Segalat, L. (2004), Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans, Neuromusc. Disorders 14, 365-370.
34. Van Drie, J. H. (2007), Monty Kier and the origin of the pharmacophore concept, Internet Electron. J. Mol. Design 6, 271-279.
35. Kier, L. B. (1967), Molecular orbital calculation of preferred conformations of acetylcholine, muscarine, and muscarone, Mol. Pharmacol. 3, 487-494.
36. Kier, L. B., MOTheory in Drug Research, Academic Press, NewYork, 1971, pp. 164-169.
37. Kier, L. B., in Danielli, J. F.; Moran, J. F.; Triggle, D. J. eds., Fundamental Concepts in Drug-Receptor Interactions, Academic Press, New York, 1970.
38. Höltje, H. D. (1974), Molecular orbital calculations for the structure of the muscarinepharmacophore, Arch. Pharm. (Weinheim) 307, 969-972.
39. Güner, O. F. ed. , Pharmacophore Perception, Development and Use in Drug Design, International Univ. Line, La Jolla, CA, 2000.
40. Mason, J. S.; Good, A. C.; Martin, E. J. (2001), 3-D pharmacophores in drug discovery, Curr. Pharm. Design 7, 567-597.
41. Langer, T.; Hoffmann, R. D. eds. , Pharmacophores and Pharmacophore Searches, Wiley-VCH, Weinheim, 2006.
42. VanDrie, J. H. (2003), Pharmacophore discovery-lessons learned, Curr. Pharm. Design 9, 1649-1664.
43. Langer, T.; Wolber, G. (2004), Pharmacophore definition and 3D searches, Drug Discov. Today: Technol. 1, 203-207.
44. Langer, T.; Hoffmann, R. D. (2006), Pharmacophore modelling: Applications in drug discovery, Exp. Opin. Drug Discov. 1, 261-267.
45. Martin, Y. C.,in Taylor, J. B., Triggle, D. J., Mason, J. S. eds., Comprehensive Medicinal Chemistry II, Computer-Assisted Drug Design (series), Vol. 4, Elsevier, Amsterdam, 2007, pp. 119-147, 515-536.
46. Laggner, C. et al. in Varnek, A.; Tropsha, A. eds. , Chemoinformatics: An Approach to Virtual Screening, Royal Society of Chemistry, Cambridge, UK, 2008, pp. 76-119.
47. Langer, T. (2010), Pharmacophores in drug research, Mol. Inform. 29, 470-475.
48. Leach, A. R.; Gillet, V. J.; Lewis, R. A.; Taylor, R. (2010), Three-dimensional pharmacophore methods in drug discovery, J. Med. Chem. 53, 539-558.
49. Barnum, D.; Greene, J.; Smellie, A.; Sprague, P. (1996), Identification of common functional configurations among molecules, J. Chem. Inform. Comput. Sci. 36, 563-571.
50. Dixon, S. L.; Smondyrev, A. M.; Knoll, E. H.; Rao, S. N.; Shaw, Da.E.; Friesner, R. A. (2006), PHASE: A new design for phamacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results, J. Comput.-Aid. Mol. Design 20, 647-671.
51. Wolber, G.; Langer, T. (2005), LigandScout: 3-D pharmacophores derived from proteinboundligandsandtheir use as virtual screening filters, J.Chem.Inform. Model.45,160-169.
52. Richmond, N. J.; Abrams, C. A.; Wolohan, P. R. N.; Abrahamian, E.; Willett, P.; Clark, R. D. (2006), GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. J. Comput.-Aid. Mol. Design 20, 567-587.
53. Jones, G.;Willett, P.; Glen, R. C. (1995),Agenetic algorithm for flexible molecular overlay and pharmacophore elucidation, J. Comput.-Aid. Mol. Design 9, 532-549.
54. Chemical Computing Group, Molecular Operating Environment, Montreal, Canada.
55. Cho, S. J.; Sun, Y. (2006), FLAME: A program to flexibly align molecules, J. Chem. Inform. Model. 46, 298-306.
56. Feng, J.; Sanil, A.; Young, S. S. (2006), PharmID: Pharmacophore identification using Gibbs sampling, J. Chem. Inform. Model. 46, 1352-1359.
57. Zhu, F.; Agrafiotis, D. K. (2007), Recursive distance partitioning algorithm for common pharmacophore identification, J. Chem. Inform. Model. 47, 1619-1625.
58. Marialke, J.; Koerner, R.; Tietze, S.; Apostolakis, J. (2007), Graph-based molecular alignment (GMA), J. Chem. Inform. Model. 47, 591-601.
59. Todorov, N. P.; Alberts, I. L.; De Esch, I. J. P.; Dean, P. M. (2007), QUASI: A novel method for simultaneous superposition of multiple flexible ligands and virtual screening using partial similarity, J. Chem. Inform. Model. 47, 1007-1020.
60. Schneidman-Duhovny, D.; Dror, O.; Inbar, Y.; Nussinov, R.; Wolfson, H. J. (2008), Deterministic pharmacophore detection via multiple flexible alignment of drug-like molecules, J. Comput. Biol. 15, 737-754.
61. Wolber, G.; Dornhofer, A. A.; Langer, T. (2006), Efficient overlay of small organic molecules using 3D pharmacophores, J. Comput.-Aid. Mol. Design 20, 773-788.
62. Taminau, J.; Thijs, G.; De Winter, H. (2008), Pharao: Pharmacophore alignment and optimization, J. Mol. Graphics Model. 27, 161-169.
63. Anghelescu, A. V.; DeLisle, R. K.; Lowrie, J. F.; Klon, A. E.; Xie, X.; Diller, D. J. (2008), Technique for generating three-dimensional alignments of multiple ligands from onedimensional alignments, J. Chem. Inform. Model. 48, 1041-1054.
64. Podolyan, Y.; Karypis, G. (2009), Common pharmacophore identification using frequent clique detection algorithm, J. Chem. Inform. Model. 49, 13-21.
65. Hoffmann, R. D., et al., in Tollenaere, J.; DeWinter, H.; Langenaeker, W.; Bultinck, P., eds. , Computational Medicinal Chemistry and Drug Discovery, Marcel Dekker, New York, 2003 pp. 461-482.
66. Steindl, T. M.; Schuster, D.; Laggner, C.; Langer, T. (2006), Parallel Screening: A novel concept in pharmacophore modeling and virtual screening, J. Chem. Inform. Model. 46, 2146-2157.
67. Steindl, T. M.; Schuster, D.; Laggner, C.; Chuang, K.; Hoffmann, R. D.; Langer, T. (2007), Parallel screening and activity profiling with HIV protease inhibitor pharmacophore models, J. Chem. Inform. Model. 47, 563-571.
68. Markt, P.; Schuster, D.; Kirchmair, J.; Laggner, C.; Langer, T. (2007), Pharmacophore modeling and parallel screening for PPAR ligands, J. Comput.-Aid. Mol. Design 21, 575-590.
69. Schuster, D.; Waltenberger, B.; Kirchmair, J.; Distinto, S.; Markt, P.; Stuppner, H.; Rollinger, J. M.; Wolber, G. (2010), Predicting cyclooxygenase inhibition by threedimensional pharmacophoric profiling. Part I: Model generation, validation and applicability in ethnopharmacology. Mol. Inform. 29, 75-86.
70. Sciabola, S.; Stanton, R.V.; Mills, J. E.; Flocco, M. M.; Baroni, M.; Cruciani, G.; Perruccio, F.; Mason, J. S. (2010), High-throughput virtual screening of proteins using GRID molecular interaction fields, J. Chem. Inform. Model. 50, 155-169.
71. Rollinger, J. M.; Schuster, D.; Danzl, B.; Schwaiger, S.; Markt, P.; Schmidtke, M.; Gertsch, J.; Raduner, S.;Wolber, G.; Langer, T. (2009), In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens, Planta. Med. 75, 195-204.
72. Keiser, Mi.J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B. (2009), Predicting new molecular targets for known drugs, Nature 462, 175-181.
73. Gregori-Puigjane, E.; Mestres, J. (2008), A ligand-based approach to mining the chemogenomic space of drugs, Combin. Chem. High Throughput Screen. 11, 669-676.
74. Paul, N.; Kellenberger, E.; Bret, G.; Mueller, P.; Rognan, D. (2004), Recovering the true targets of specific ligands by virtual screening of the Protein Data Bank, Proteins 54, 671-680.
75. Ekins, S.; Mestres, J.; Testa, B. (2007), In silico pharmacology for drug discovery: Applications to targets and beyond, Br. J. Pharmacol. 152, 21-37.